Prevention and management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

2 Answers

### Management of Delayed Cerebral Ischemia (DCI) Post-SAH **1. Prophylaxis: Nimodipine Protocol** * **Standard Care:** Oral nimodipine is the only medication proven to improve neurological outcomes (by reducing DCI, not necessarily angiographic vasospasm) in patients with aneurysmal SAH. * **Dosing:** 60 mg orally (or via gastric tube) every 4 hours, starting within 96 hours of SAH onset and continuing for 21 days. * **Caveat:** If hypotension occurs, the dose may be reduced to 30 mg every 2 hours, but it should rarely be discontinued. **2. Monitoring for Vasospasm** * **Transcranial Doppler (TCD):** Performed daily or every other day to monitor flow velocities. A mean flow velocity (mFV) in the MCA > 200 cm/s or a Lindegaard ratio (MCA mFV / extracranial ICA mFV) > 6 is highly suggestive of significant vasospasm. * **Clinical Assessment:** The most sensitive "monitor" is a serial neurologic exam to detect new focal deficits or a decline in GCS. **3. Management of Symptomatic Vasospasm (DCI)** * **Step 1: Induced Hypertension:** * The "Triple-H" therapy (Hypervolemia, Hypertension, Hemodilution) has evolved. Current guidelines emphasize **euvolemia** and **induced hypertension**. * **Goal:** Increase Mean Arterial Pressure (MAP) using vasopressors (e.g., norepinephrine) until clinical deficits resolve or a maximum tolerated pressure is reached (e.g., SBP 180-200 mmHg). * **Step 2: Endovascular Intervention:** * Indicated if clinical deficits do not improve with induced hypertension or if hypertension is contraindicated. * **Intra-arterial (IA) Vasodilators:** IA verapamil, nicardipine, or milrinone can provide temporary relief of spasm. * **Balloon Angioplasty:** Considered for focal, high-grade vasospasm in proximal large vessels (e.g., M1, A1, ICA terminus). It provides more durable relief than IA vasodilators. **4. Supportive Measures** * Maintain normoglycemia, normothermia, and normocapnia. * Seizure prophylaxis is often used in the acute phase (3-7 days), though long-term use is not routinely recommended unless seizures occur. **References:** 1. Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the AHA/ASA. *Stroke*. 2012. 2. Diringer MN, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. *Neurocrit Care*. 2011. 3. Pickard JD, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. *BMJ*. 1989.

### Prevention and Management of Cerebral Vasospasm after Aneurysmal SAH **1. Definitions and Clinical Context** Cerebral vasospasm is a leading cause of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (SAH). It typically occurs 4 to 14 days after the initial bleed (peak day 7–10). This patient (55F, Fisher Grade 3) is at high risk due to the significant amount of blood seen on initial imaging. **2. Prophylaxis: The Role of Nimodipine** * **Standard Protocol:** Nimodipine 60 mg orally every 4 hours for 21 days is the only treatment proven to improve neurological outcomes in SAH. * **Mechanism:** It primarily works by reducing the incidence of DCI and improving clinical recovery, though it does not significantly reduce the radiographic appearance of vasospasm itself. * **Safety:** Monitor for hypotension; the dose may be halved (30 mg every 2 hours) if blood pressure is unstable. **3. Monitoring: TCD and Clinical Exam** * **Transcranial Doppler (TCD):** Elevated mean velocities (e.g., MCA >200 cm/s) or a rapid daily increase suggest vasospasm. The Lindegaard ratio (MCA/ICA ratio >3) helps distinguish vasospasm from hyperemia. * **Clinical Exam:** The "gold standard" for DCI is a new focal neurological deficit or a decline in GCS (≥2 points) not explained by other factors. **4. Management of Symptomatic Vasospasm** * **Induced Hypertension:** The cornerstone of medical management. The goal is to improve cerebral perfusion pressure. MAP targets are often 20-30 mmHg above baseline (e.g., SBP 160–180 mmHg). The "Triple H" therapy (Hypertension, Hypervolemia, Hemodilution) has largely been superseded by "Induced Hypertension" while maintaining euvolemia. * **Endovascular Intervention:** If medical management fails or deficits persist, urgent digital subtraction angiography (DSA) with intra-arterial vasodilators (e.g., Verapamil, Nicardipine) or balloon angioplasty is indicated. **References:** 1. Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012 (reaffirmed 2021). 2. Pickard JD, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. *BMJ*. 1989. 3. Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after subarachnoid hemorrhage. *Crit Care*. 2016.